BioLineRx highlights Phase 1/2a GLIX1 trial in recurrent high-grade glioma at SNO meeting
BLRX•BioLineRx said it will present two GLIX1 posters at the Society for Neuro-Oncology annual meeting in Philadelphia on Nov. 13, 2026, including preclinical findings and the design of an ongoing Phase 1/2a trial.
1. Two posters scheduled
BioLineRx disclosed two GLIX1 posters for the Society for Neuro-Oncology annual meeting in Philadelphia on Nov. 13, 2026. One will describe preclinical anti-tumor activity in multiple glioblastoma models, including treatment-resistant disease; the other will outline the design of an ongoing trial of oral GLIX1 in recurrent or progressive high-grade glioma.
